review · Viruses
Hepatitis B and C viruses are primary causes of end-stage liver disease worldwide. Although an effective vaccine exists for Hepatitis B (HBV), new infections persist, especially in regions with poor vaccination programmes. The vaccine does not benefit those already infected, as chronic HBV has no cure. There are significant gaps in understanding HBV's biology, pathogenesis, and genomic features, including their role in establishing and maintaining infection. Current knowledge regarding the virus's impact on disease progression and treatment response, particularly in hyperendemic areas, is inadequate. This review highlights the critical need for in-depth studies into viral biology to develop improved management strategies for infected individuals, more effective preventative measures, and to guide the search for a cure. It discusses advances in understanding the genomic basis of viral activities, the complex interplay between the virus and its host, and the effects of coinfections.
Hepatitis B is a major global health threat, causing severe liver disease and death, with no cure for chronic infection. Understanding its complex biology is vital to develop new treatments and more effective prevention methods, particularly for vulnerable populations in regions with high infection rates. This research aims to fill critical knowledge gaps to improve patient outcomes.
The abstract indicates early-stage research focused on understanding Hepatitis B virus biology and pathogenesis. This foundational knowledge is essential for informing the development of future therapeutic interventions, such as new antiviral drugs or improved management strategies for chronically infected individuals, and more effective preventative measures, including next-generation vaccines. It could also guide the search for a cure.
AI-generated from the published abstract. Always read the original work before citing.
Hepatitis B and C viruses (HBV and HCV) are the leading causes of end-stage liver disease worldwide. Although there is a potent vaccine against HBV, many new infections are recorded annually, especially in poorly resourced places which have lax vaccination policies. Again, as HBV has no cure and chronic infection is lifelong, vaccines cannot help those already infected. Studies to thoroughly understand the HBV biology and pathogenesis are limited, leaving much yet to be understood about the genomic features and their role in establishing and maintaining infection. The current knowledge of the impact on disease progression and response to treatment, especially in hyperendemic regions, is inadequate. This calls for in-depth studies on viral biology, mainly for the purposes of coming up with better management strategies for infected people and more effective preventative measures for others. This information could also point us in the direction of a cure. Here, we discuss the progress made in understanding the genomic basis of viral activities leading to the complex interplay of the virus and the host, which determines the outcome of HBV infection as well as the impact of coinfections.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/v16050724
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
